[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostatic-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostatic-hyperplasia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,84,118,144,171,203,231,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100312974","profiling-of-radiological-factors-in-treatment-and-outcomes-in-prostate-cancer-100312974",false,"NCT03354416","Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer","* INCLUSION CRITERIA:\n* Patients with an increased risk for prostate cancer (strong family history and\u002For germline mutation in DNA repair genes), or with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.\n* Age greater than or equal to 18 years\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-none","MALE","18 Years",{"count":18,"type":19},10000,"ESTIMATED","OBSERVATIONAL","Background:\n\nProstate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a profile of prostate cancer. They want to collect data to make diagnosis and treatments better.\n\nObjectives:\n\nTo gather data about the radiological and clinical course of prostate cancer. To study imaging-based biomarkers of prostate cancer.\n\nEligibility:\n\nMen ages 18 and older with diagnosed or suspected prostate cancer\n\nDesign:\n\nParticipants will give permission for researchers to use their medical history and records. Their data will be reviewed, collected, and analyzed. These include results of their tests and scans.\n\nSponsoring Institution: National Cancer Institute",[23,24,25,26,27],"Prostatic Cancer","Prostatic Neoplams","Prostatic Hyperplasia","Prostate Cancer","Cancer Of Prostate",[29,30,31,32,33,34],"Imaging-Based Prognostic Markers","Multiparametric MRI (mpMRI)","Translation of Imaging into Treatment Decisions","Decision-Support System","Artificial Intelligence Research","Natural History","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2018-02-26",{"date":43,"type":19},"2033-12-31",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100559562","eeap-using-moses-20-technology-vs-the-thulium-fiber-laser-in-medium-large-prostates-100559562","NCT06565741","EEAP Using Moses 2.0 Technology vs the Thulium Fiber Laser in Medium-Large Prostates","Prospective and Randomized Analysis of Endoscopic Prostate Enucleation Using Moses 2.0 Technology Versus the New Thulium Fiber Laser in Medium and Large Prostates.","Inclusion Criteria:\n\n* Males aged between 40 and 90 years.\n* Patients who, due to their lower urinary tract symptoms, are candidates for\n\nBPH surgery, including:\n\n* Obstructive urinary symptoms evaluated through IPSS with a score \\>7 and QoL \\> 2 or acute urinary reten on refractory to catheter removal.\n* Obstructive urinary flow evaluated through uroflowmetry with Qmax\\< 15 ml\u002Fs, obstruction demonstrated by pressure\u002Fflow study, prostatic origin haematuria refractory to medical treatment, or acute urinary retention refractory to catheter removal.\n\n  * Prostatic volume measured by transabdominal ultrasound, transrectal ultrasound, or magnetic resonance imaging of more than 80 cc.\n  * Prostate-specific antigen (PSA) \\< 4 ng\u002Fml, or with multiparametric prostate magnetic resonance imaging reporting PIRADS \\< 3 or equal to 3 with PSA density \\< 15%.\n\nExclusion Criteria:\n\n* Diagnosis, suspicion, or history of urethral stenosis or urethral surgery.\n* History of prostate surgery or pelvic radiotherapy.\n* Diagnosis or suspicion of prostate cancer or urothelial cancer.\n* Body mass index superior to 30.","40 Years","90 Years",{"count":58,"type":19},120,"INTERVENTIONAL",[61],"NA","Introduction: Endoscopic anatomical enucleation of the prostate (EEAP) with lasers has emerged as an effective and less invasive surgical option compared to traditional methods. Among the various available laser options, Holmium laser and Thulium Fiber laser have stood out as two prominent approaches for performing endoscopic prostate enucleation. These technologies have 3 showcased their effectiveness in ablating prostatic tissue and improving urinary symptoms. Nevertheless, differences in their physical properties and modes of action may impact their success rates and clinical outcomes. In our institution it is standard practice to use one laser or the other according to their availability in the operating room.\n\nPrimary Objective: To demonstrate the superiority of MoLEP over ThuFLEP in terms of enucleation efficiency.\n\nSecondary Objectives: a) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of perioperative bleeding.\n\nb) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of postoperative hospital stay.\n\nc) To demonstrate the non-inferiority of ThuFLEP compared to ThuFLEP in terms of perioperative complications.\n\nd) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of improvement in urinary symptoms.\n\ne) To demonstrate the non-inferiority of MoLEP compared to ThuFLEP in terms of improvement in flowmetric variables.\n\nStudy Type: Prospective, randomized, non-blind, multicentric clinical trial. Intervention: Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.",[25,64,65],"Surgery","Endoscopic Anatomical Enucleation of the Prostate (EEAP)",[67,68,69,70,71,72],"Medium and Large Prostates","Endoscopic Prostate Enucleation","Endoscopic anatomical enucleation of the prostate (EEAP)","Holmium laser","Thulium Fiber laser","Moses 2.0 Technology","2026-04-23",{"date":75,"type":39},"2026-04-29",{"date":77,"type":39},"2024-09-03",{"date":79,"type":19},"2028-09",{"name":81,"class":82},"Fundacio Puigvert","OTHER",3,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":59,"phases":95,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100635690","comparing-clean-intermittent-self-catheterization-and-indwelling-catheterization-for-the-management-of-urinary-retention-before-bph-surgery-100635690","NCT07555964","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.l","CATHETERS","Inclusion Criteria:\n\n* Men over 50 years old;\n* Confirmed diagnosis of benign prostatic hyperplasia (BPH);\n* Prostate volume greater than 40 grams;\n* Presence of acute urinary retention with failure to wean from the catheter despite medical treatment with alpha-blocker for at least 48 hours\n* Indication for surgical management of BPH;\n* Patient affiliated with or a beneficiary of a social security scheme;\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patient with a history of prostate surgery (including BPH surgery), prostatic artery embolization or Urolift implant placement are not considered a history of prostate surgery;\n* Patient with symptomatic urethral stricture;\n* Patient with a bladder emptying disorder of neurogenic origin;\n* Patient with an anatomical contraindication to ICSC (urethral stricture, false urethral route);\n* Patient who had urine drainage by suprapubic catheter\n* Patient with motor, neurological, anatomical, or cognitive difficulties preventing the education or learning of ICSC;\n* Patient contraindicated for surgical management of their BPH;\n* Patient unable to understand the research documents and provide informed consent;\n* Persons subject to legal protection measures or placed under judicial protection.","50 Years",{"count":94,"type":19},106,[61],"The CATHETERS trial is a multicenter, randomized, open-label superiority study comparing two methods of managing urinary retention before surgery for benign prostatic hyperplasia (BPH): clean intermittent self-catheterization (ICSC) versus indwelling catheter (IDC). The primary objective is to determine whether ICSC reduces the occurrence of infectious complications (urinary bacterial colonization requiring antibiotic therapy, urinary tract infection, or urosepsis) compared to IDC in men awaiting BPH surgery. A total of 106 patients will be enrolled across multiple centers in France, with follow-up extending to three months after surgery.",[25,98,99,100,101,102],"Urinary Retention","Urinary Catheterization","Intermittent Urethral Catheterization","Urinary Tract Infections","Surgical Procedures",[104,105,106,107],"BPH","ICSC","IDC","Urinary Tractus Infection","NOT_YET_RECRUITING","2026-04-21",{"date":75,"type":39},{"date":112,"type":19},"2026-04-24",{"date":114,"type":19},"2028-04-24",{"name":116,"class":82},"University Hospital, Bordeaux",5,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":125,"minAge":16,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":59,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":117},"100635674","an-international-multicenter-clinical-study-on-application-of-uromed-ai-doctor-based-on-large-language-models-100635674","NCT07555756","An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models","AN INTERNATIONAL MULTICENTER CLINICAL STUDY ON APPLICATION OF UROMED AI DOCTOR BASED ON LARGE LANGUAGE MODELS","Inclusion Criteria:\n\n* Diagnosed with kidney stones, benign prostatic hyperplasia, or bladder cancer in line with the Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases (2022 Edition) and requiring hospitalization for surgery.\n\nAged 18 to 60 years with good communication skills. Voluntarily agrees to participate in the clinical study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Suffers from psychiatric disorders. Refuses to participate in medical activities involving the use of artificial intelligence systems.\n\nUnable to engage in effective communication with the research team. Has multiple underlying diseases with unstable clinical conditions.","ALL","60 Years",{"count":128,"type":19},1080,[61],"This study evaluates our team's urology-specific AI (UroMed AI Doctor) for its safety, professionalism, knowledge and Q\\&A ability, and tests its effectiveness against traditional manual urology care, to confirm if it can be a safe auxiliary tool and improve patients' preoperative experience.\n\nBefore the study, we will test the AI with urology questions, compare it to international AI models (DeepSeek, ChatGPT, Google Gemini), and have two senior chief physicians evaluate it.\n\nIn the clinical trial, patients at The First Affiliated Hospital of Guangxi Medical University will be randomly split into two groups: AI-assisted care or traditional care by a specialist.\n\nTwo senior specialists will evaluate both groups blindly; each group will get preoperative education (AI or physician), with anxiety and satisfaction surveyed.\n\nSubsequently, a multi-center validation will be conducted with 11 domestic and international hospitals.",[132,25,133],"Kidney Calculi","Urinary Bladder Neoplasms",[135,136],"UroMed AI Doctor","Urology",{"date":75,"type":39},{"date":139,"type":19},"2026-05-01",{"date":141,"type":19},"2029-07-31",{"name":143,"class":82},"First Affiliated Hospital of Guangxi Medical University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":59,"phases":154,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100528494","phase-2-surface-electrical-stimulation-for-urinary-incontinence-in-men-treated-for-prostate-cancer-100528494","NCT06161506","Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","* INCLUSION CRITERIA:\n* Participants must be male.\n* Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.\n* Participants must have at least one of the following types of urinary incontinence:\n\n  * stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing\n  * urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.\n* Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.\n* Participants must be able to read and write in English.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C= 2.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Change of therapy for prostate cancer planned during the study intervention.\n* History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.\n* Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (\\>= 4 UTIs within the 12 months prior to the study treatment initiation).\n* History of complete denervation of the pelvic floor.\n* Severe obesity (body mass index \\[BMI\\] \\>35).\n* Pelvic pain\u002Fpainful bladder syndrome.\n* Metal implant in the abdominal or pelvic area.\n* History of chronic cough with ongoing symptoms\n* An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.\n* History of epilepsy.\n* History of underlying neurologic\u002Fneuromuscular disorder that could contribute to urinary incontinence.\n* Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.\n* Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.","120 Years",{"count":153,"type":19},41,[155],"PHASE2","Background:\n\nMen who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.\n\nObjective:\n\nTo see if the Elidah device can reduce urinary incontinence after prostate treatment.\n\nEligibility:\n\nMen aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.\n\nDesign:\n\nParticipants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.\n\nThe Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.\n\nParticipants will be given an Elidah device and taught how to use it at home.\n\nThey will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.\n\nParticipants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.\n\nParticipants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.\n\nParticipants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.\n\nParticipants will complete 15-minute questionnaires.",[158,159,25],"Urinary Urge Incontinence","Stress Urinary Incontinence",[161,162,26],"Elidah Device","Urinary Incontinence","2026-04-14",{"date":165,"type":39},"2026-04-15",{"date":167,"type":39},"2024-02-15",{"date":169,"type":19},"2028-03-01",{"name":45,"class":46},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":125,"minAge":16,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":181,"conditions":182,"keywords":187,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":47},"100534691","clinical-application-of-the-j-pet-scanner-prototype-100534691","NCT06242119","Clinical Application of the J-PET Scanner Prototype","Clinical Use of a J-PET Scanner Prototype Made of Plastic Scintilators","JPET2Clinic","Inclusion Criteria:\n\n* The patient is referred for a PET\u002FCT scan, in accordance with recognized indications for examining the entire body.\n* Age over 18 years\n* Informed, voluntary consent to participate in the study\n\nExclusion Criteria:\n\n* Pregnant women, breastfeeding women\n* People with a previously diagnosed allergy to radiopharmaceuticals\n* Age under 18 years\n* Lack of cooperation with the patient\n* Lack of informed consent to participate in the study",{"count":180,"type":19},25,"Positron emission tomography (PET), an advanced diagnostic imaging technique, exploits the annihilation of positrons (e+) to delineate pathological alterations within diseased tissues. Integral to PET scanners are detector systems that transform gamma photons into fluorescent photons, thereby gleaning insights into the energy, time, and spatial distribution of gamma photons emanating from positron-emitting radiopharmaceuticals. Conventional PET scanners, bear a significant financial burden primarily due to their reliance on LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. The exorbitant cost and limited availability of these crystal scintillators impede the widespread adoption of PET scanners. In a departure from conventional PET technology, the prototype J-PET scanner employed in this trial employs plastic scintillators, characterized by unique physical properties. This prototype is further equipped with bespoke software enabling three-photon imaging based on the annihilation of ortho-positronium (o-Ps) generated within diseased tissue. This study delves into the clinical applicability of PET scanners employing plastic scintillators, particularly investigating the feasibility of PET imaging using plastic scintillators where gamma quanta interact by mechanisms other than the photoelectric effect. Furthermore, this study endeavors to contemporaneously acquire and analyze data related to the lifetime of ortho-positronium (o-P) atoms emanating from routine radiopharmaceuticals. Additionally, it seeks to validate the utilization of a novel diagnostic indicator, termed the \\"positron biomarker,\\" through a prospective study, comparing its efficacy to conventional diagnostic PET scanning methodologies.",[26,25,183,184,185,186],"Prostatic Neoplasms","Prostate Cancer Metastatic","Neuroendocrine Tumors","Neuroendocrine Carcinoma",[188,189,190,191,192,193],"positronium","PET","[18F]FDG","[18F]choline","[68Ga]Ga-DOTA-TATE","[68Ga]Ga-PSMA","2025-02-17",{"date":196,"type":39},"2025-02-19",{"date":198,"type":39},"2024-03-07",{"date":200,"type":19},"2025-10-30",{"name":202,"class":82},"Jagiellonian University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":59,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":83},"100492006","clinical-trial-on-the-effectiveness-of-tumt-compared-to-pae-in-reducing-severe-luts-in-men-with-bph-100492006","NCT05686525","Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men with BPH","Non-inferiority, Randomised, Open-label Clinical Trial on the Effectiveness of Transurethral Microwave Thermotherapy Compared to Prostatic Artery Embolisation in Reducing Severe Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia","TUMT-PAE-1","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign an informed consent.\n* Diagnosis of LUTS secondary to BPH refractory to\u002Fcontraindicated for medical treatment or not patient preference.\n* Severe urinary symptoms on IPSS (IPSS score ≥ 20).\n* Bladder outlet obstruction (BOO) is defined by Qmax ≤ 15ml\u002Fsec, based on uroflowmetry.\n* Prostate volume at minimum 50 ml measured by TRUS or MR.\n* Men with prostate cancer in Active Surveillance or Watchful Waiting who have LUTS due to a large BPH component are allowed.\n* Indwelling catheter or intermittent catheter is allowed. In this case baseline IPSS is 35 points.\n\nExclusion Criteria:\n\n* Active bladder cancer (patients with pTa low-grade tumors are allowed).\n* Previous pelvic radiation for cancer treatment.\n* Bladder stones (inclusion is allowed after removal).\n* Current urethral strictures or bladder neck contracture.\n* Neurogenic LUTS.\n* Symptomatic urinary tract infection at the time of intervention.\n* Documented bacterial prostatitis in the last year.\n* Severe atheromatous disease or other pathology preventing catheter-based intervention (as rated on CT angiography by an interventional radiologist).\n* Allergy to iodinated contrast media.\n* Renal failure defined as estimated glomerular filtration rate (eGFR) \\\u003C 35ml\u002Fmin.\n* High bleeding risk (spontaneous international normalized ratio (INR) \\> 1.6).\n* Contraindication to conscious sedation (if requested by the patient).\n* Prostate median lobe defined by treating physician.\n* Urethral colliculus to bladder neck length \\\u003C35mm.",{"count":212,"type":19},220,[61],"The TUMT-PAE-1 trial is a randomised clinical trial aiming to compare the effectiveness of transurethral microwave thermotherapy (TUMT) with prostatic artery embolisation (PAE) in reducing urinary symptoms caused by prostate gland enlargement. The assessment will be done by patient reported and functional outcome measures. The primary purpose is to evaluate the urinary symptoms six months after the procedure, measured by the International Prostate Symptom Score (IPSS).",[25,216],"Lower Urinary Tract Symptoms",[218,219,220,221],"Embolization, Therapeutic","Prostatic Artery Embolization","Transurethral Microwave Thermotherapy","Patient Reported Outcome Measures","2025-01-10",{"date":224,"type":39},"2025-01-13",{"date":226,"type":39},"2022-10-27",{"date":228,"type":19},"2030-12",{"name":230,"class":82},"Rigshospitalet, Denmark",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":59,"phases":240,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100550888","eep-in-patients-with-urodynamically-proven-duda-100550888","NCT06452927","EEP in Patients With Urodynamically Proven DU\u002FDA","Endoscopic Enucleation of the Prostate in Patients With Urodynamically Proven Detrusor Underactivity\u002FAcontractility","Inclusion Criteria:\n\n* Endoscopic enucleation of the prostate in patients with DU\u002FDA secondary to a non-neurogenic aetiology:\n\n  * Detrusor underactivity (DU) defined urodynamically as a bladder contractility index (BCI) of \\\u003C100.\n  * Detrusor acontractility (DA) defined urodynamically as the absence of a detrusor contraction despite filling to bladder capacity.\n\nExclusion Criteria:\n\n* Neurogenic aetiology for DU\u002FDA (Parkinson, stroke…)\n* Other surgical approaches for the treatment of benign prostate hyperplasia (Aquaablation, open enucleation of the prostate, open prostatectomy, transurethral resection of the prostate...)",{"count":239,"type":19},300,[61],"The aim of this project is to create und evaluate a multicentral, retro-\u002Fprospective database for patients with urodynamically proven detrusor underactivity (DU) or acontractility (DA) secondary to a non-neurogenic aetiology, who undergo endoscopic, anatomic enucleation of the prostate (EEP).",[216,243,244,245,25],"Lower Urinary Tract Obstructive Syndrome","Detrusor Underactivity","Detrusor Areflexia",[247,248,249,244,250,251,252,253],"Endoscopic Enucleation of the Prostate","BipoEP","ThuLEP","Detrusor Acontractility","HoLEP","Urodynamics","Pressure Flow Study","2024-06-06",{"date":256,"type":39},"2024-06-11",{"date":258,"type":19},"2024-09",{"date":79,"type":19},{"name":261,"class":262},"EEPiDuDa Study Group","NETWORK",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":59,"phases":272,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":286},"100516215","phase-4-prostate-medication-metabolism-and-gut-microbiota-100516215","NCT06001619","Prostate Medication, Metabolism and Gut Microbiota","PROMED","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Ability and stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* Any history of a fecal transplantation.\n* Recent (within 3 months or still symptomatic) gastroenteritis.\n* Antibiotic treatment within 3 months (expect for antibiotic prophylaxis related to prostate biopsies).\n* Inability to comply with the protocol of unwillingness to participate in the study.",{"count":271,"type":19},100,[273],"PHASE4","PROMED is a prospective, single center translational multiple cohort study to investigate the association of prostate medication and gut microbiota. The main aim is to investigate how prostate hormonal therapy (5-ARI, ADT) affects gut microbiota composition. Aalso study metabolic characteristics in the gut and systemic circulation in men with different medications will be studied. In addition, the effect of gut microbiota on patient's response to medications will be investigated. The medicines used in the study to treat benign prostate hyperplasia are dutasteride and finasteride and a combination of dutasteride and tamsulosin. LHRH antagonist degarelix is used as a medication to treat patients with cancer. The dosages of 5-ARI medication: dutasteride 0,5mg x1 or finasteride 5mg x1 or combination of dutasteride and tamsulosin 0,5\u002F0,4mg x1. The starting dose of LHRH antagonist degarelix is 120mgx2 and the maintenance dose is 80mgx1. The medication for PCa is planned according to the protocol but so that each subject receives degarelix at the beginning of treatment and one month after initiation. Thereafter, the medication is continued according to the clinician's assessment. The study is carried out in Turku University Hospital and University of Turku.",[25,26],"2023-08-17",{"date":278,"type":39},"2023-08-21",{"date":280,"type":39},"2022-12-01",{"date":282,"type":19},"2026-12-31",{"name":284,"class":285},"Turku University Hospital","OTHER_GOV",2]